Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Common Stock Issued

Cash raised by issuing new shares.

Seer, Inc.NASDAQ: SEER

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued outflow grows to $14K

Q1 FY2026 common stock issued was $14K, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $449K.

Context

  • Common stock issued amounted to 2.8% of revenue in FY2025, up 2.8 pp from a year earlier.
  • Common stock issued increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock issued holds near $14K or moves back toward the trailing-twelve-month quarterly average of $112.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14K-93.0% QoQ
Last fiscal yearDec 2025
$458K— YoY
LTMMar 2026
$449K— YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
458K USD
Year-over-year change
—
4-year CAGR
-74.2%

Common Stock Issued vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Common stock issued amounts to 3.0% of revenue for SEER, versus a peer median of 704.5%.
SEER Competitors
Common Stock Issued for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYMRKymera Therapeutics, Inc.LTM Jun 2026$739.68M USD+199.9%+87.8%704.5%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$556.34M USD+179.3%——
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$358.67M USD+602.6%+14.8%835.0%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$308M USD+17301.2%+114.8%—
NRIXNurix Therapeutics, Inc.LTM Aug 2026$261.21M USD+29.5%+130.8%37.2%
SANASana Biotechnology, Inc.LTM Mar 2026$127.76M USD+172.2%+197.3%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$126.82M USD+1104.7%+445.8%363.8%
PEPGPepGen Inc.LTM Mar 2026$109.49M USD+6044.2%-1.8%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$102.13M USD+7762.1%+65.6%329448.4%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$50.88M USD-51.5%-16.6%180.3%
QSIQuantum-Si incorporatedLTM Mar 2026$46.83M USD+0.1%+225.9%2528.5%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$37.38M USD+42373.9%-88.3%—
STTKShattuck Labs, Inc.LTM Mar 2026$26.22M USD+2495.6%+538.3%2621.6%
PHVSPharvaris N.V.LTM Sep 2026€6.56M EUR-96.2%+161.4%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$1.47M USD-99.5%-49.4%—
SEERSeer, Inc.LTM Mar 2026$449K USD——3.0%
NKTXNkarta, Inc.LTM Mar 2026$147K USD+124.0%-91.3%—
MOLNMolecular Partners AGLTM Mar 2026CHF 73.01K CHF+82.5%-36.8%—
MNOVMediciNova, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding SEER) —+179.3%+76.7%704.5%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Depreciation & Amortization2.56M3.94M5.58M6.18M7.25M
Deferred Income Tax1.2M0000
Stock-Based Compensation25.93M33.67M34.42M28.21M15.41M
Change in Working Capital(5.87M)(7.09M)(2.72M)(144K)(579K)
Accounts Receivables(2.5M)(2.87M)302K487K277K
Inventory(3.59M)(1.59M)(1.95M)(2.67M)(2.9M)
Accounts Payables1.6M(1.55M)(987K)3.36M1.06M
Other Working Capital(1.38M)(1.07M)(91K)(1.32M)983K
Other Non-Cash Items1.01M1.66M(10.07M)6.25M7.07M
Operating Cash Flow(46.35M)(60.78M)(59.07M)(46.11M)(44.45M)
Capital Expenditures(6.92M)(10.27M)(7.31M)(3.58M)(1.8M)
Acquisitions (Net)163.96M0000
Purchases of Investments(279.96M)(366.27M)(403.09M)(272.93M)(173.17M)
Sales of Investments116M253.65M448.31M342.03M237.81M
Other Investing Activities(163.96M)170K0343K(1.3M)
Investing Cash Flow(170.88M)(122.72M)37.9M65.86M61.55M
Debt Repayment00000
Common Stock Issued102.96M000458K
Common Stock Repurchased(35K)(20K)(13K)(11.82M)(10.2M)
Dividends Paid00000
Other Financing Activities13.71M3.91M465K321K(827K)
Financing Cash Flow116.63M3.89M452K(11.5M)(10.57M)
Effect of Forex Changes00000
Net Change in Cash(100.59M)(179.61M)(20.71M)8.25M6.53M
Free Cash Flow(53.27M)(71.05M)(66.37M)(49.69M)(46.25M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.